BioNTech in conflict with regulator over new COVID vaccine nod: WAS newspaper
The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
Berlin: The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday.
The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to submit any new clinical trials, WAS reported, citing the Financial Times.
The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.
The head of the German medical regulator, Paul Ehrlich Institute (PEI), Klaus Cichutek, told the newspaper there was no reason to risk bypassing the standard regulatory process during preparations for the next pandemic wave.
"Mr. Sahin demands that only animal data be submitted for approval of variant vaccines," the PEI chief told WAS, adding this could be done in an emergency but there was no emergency at the moment.
According to the PEI and the European Medicines Agency (EMA), first approvals for updated COVID-19 vaccines could be given in September if the drugmakers prove their superiority over existing vaccines in human trials, WAS reported.
Read also: Pfizer-BioNTech COVID vaccines effective, safe for children aged 6 months to 4 years: USFDA staff
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.